KCT0004290已完成未知
Phase I clinical trial to compare the pharmacokinetics and safety of RDN18002 with co-administration of sitagliptin and empagliflozin in healthy adult volunteers
Huons0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 45(Year)（—）
- 性别
- All
入选标准
- •1) Healthy adult subject older than 19 to 45 years at the time of screening
- •2) Body weight more than 50kg and Body Mass Index(BMI) 18.0kg/m2 ~ 29.0 kg/m2
- •? BMI(kg/m2) = Body weight (kg) / {height (m)}2
- •3) Subject judged to be eligible by Physical examination and interview conducted according to the study protocol. Thus, subject should not have congenital/chronic disease or pathological symptoms/findings
- •4) Subject judged to be eligible by clinical laboratory tests such as hematology test, blood chemistry test, serum electrolyte test, urine test, Urine Microscopy urine test, serology test performed according to the study protocol
- •5) Subject who fully understands the clinical trials after in-depth explanation, volunteers to join the clinical trials and signs inform consent
排除标准
- •1) Subject with currently or a history of cardiovascular , respiratory, hepatic, renal, neurological, endocrine, hemato-oncology, psychiatric, urinary diseases that is clinically significant
- •2) Subject with a history of pancreatitis
- •3) Subject with Type 1 diabetes or diabetic ketoacidosis
- •4) Subject with a history of gastrointestinal disorders (Crohn's disease, ulcer, acute or chronic pancreatitis, etc.) or gastrointestinal surgery (excluding simple cecal surgery or hernia surgery) that may affect the absorption of pharmaceuticals for clinical trials
- •5) Subject with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
- •6) Subject with with a history of hypersensitivity reactions or clinically significant hypersensitivity reactions to drugs including sitagliptin, empagliflozin or other drugs (including aspirin, antibiotics, etc)
- •7) Systolic blood pressure =100mmHg or = 150mmHg, diastolic blood pressure =55mmHg or = 95mmHg at the time of screening
- •8) Subject with the following results in the clinical laboratory tests
- •- Aspartate Transaminase(AST) or Alanine Transaminase(ALT) > 2 x upper limit of normal range
- •- Total Bilirubin > 2.0 mg/dl
- •- CK > 2 x upper limit of normal range
- •- eGFR < 60 mL/min/1.73m2
- •9) Subject who takes alcohol > 21 units/week, 1unit=10g=12.5ml of pure alcohol) or can’t stop drinking during the clinical trials
- •10) Subject who smokes> 10 cigarettes/day or can’t stop smoking during the clinical trials
- •11) Subject who have received medication involved in other clinical trials within 6 months before the first administration
- •12) Subject who have donated whole blood donation within 60 days, component blood donation within 30 days or have received blood transfusions before the first administration
- •13) Subject taking any ETC or herbal medicine, within 2 weeks or taking any OTC within 1weeks before the first administration (However, if the drug does not affect the pharmacokinetic properties of the clinical trial drug, it may be taken at the discretion of the Investigator.)
- •14) Subject taking metabolizing enzyme inducers or inhibitors such as barbitals within 1 month before the first administration
- •15) Subject with mental illness or substance abuse
- •16) Subject who have consumed food which can significantly change the absorption, distribution, metabolism and excretion of a Investigational drug within 7 days before the first administration (such as grapefruit or its components)
- •17) Subject who do not agree with the approved method of contraception during the clinical trial
- •* Approved method of contraception: Blockage(condoms, Diaphragm etc.) with other contraception(infertility operation, intrauterine contraceptive device, oral contraceptive pill, hormone, contraceptive cream, jelly or foam etc.)
- •18) Subject deemed inappropriate to participate in the clinical trial for clinical laboratory test results or other reasons
- •19) Female subject with pregnancy, serum/urine hCG Positive or breast-feeding
研究者
相似试验
已完成
不适用
Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy VolunteersCertain infectious and parasitic diseasesKCT0001811Chong Kun Dang24
尚未招募
不适用
Pharmacokinetic drug interaction between celecoxib and rebamipideKCT0000381Hanlim Pharmaceutical30
已完成
Unknown
Studying the safety and the pharmacokinetics after single dosing of KDF2001 in healthy adultEndocrine, nutritional and metabolic diseasesKCT0009163Kyung Dong Pharmaceutical40
已完成
不适用
A Phase 1 Study to Compare the Pharmacokinetics of CAL-101 Capsules to Tablets in Healthy Male Subjects.Blooddiseaseleukemia/lymophoma10047954NL-OMON35094Calistoga Pharmaceuticals Inc.15
进行中（未招募）
1 期
A research study of how fast-acting insulin aspart works in the body of children, young people and grown-ups with type 1 diabetesDiabetes Mellitus, Type 1MedDRA version: 20.0Level: LLTClassification code 10045228Term: Type I diabetes mellitusSystem Organ Class: 100000004861EUCTR2017-002014-31-DEovo Nordisk A/S43